Signals, Powered By EquityPandit
On Thursday, Cipla the pharma major has completed the acquisition of InvaGen and Exelan.
This acquisition has come as a major positive for Cipla to scale its business in US as the combined revenue for both these companies in 2015 stood at USD 230 million.
Umang Vohra, the COO of Cipla said in an interview that the current growth guidance of company did not include this merger and it will be a part of it in the next fiscal.
